Class-Sparing Regimens for Initial Treatment of HIV-1 Infection
May 15, 2008
A regimen of either efavirenz or lopinavir-ritonavir plus two nucleoside reverse-transcriptase inhibitors (NRTIs) is recommended for HIV-1 patients starting initial therapy; however, it is not known which of these two regimens has greater efficacy. The alternative regimen of lopinavir-ritonavir plus efavirenz could prevent toxic effects associated with NRTIs, the study authors noted.
"Virologic failure was less likely in the efavirenz group than in the lopinavir-ritonavir group," the authors concluded. "The virologic efficacy of the NRTI-sparing regimen was similar to that of the efavirenz group but was more likely to be associated with drug resistance."
New England Journal of Medicine
05.15.2008; Vol. 358; No. 20: P. 2095-2106; Sharon A. Riddler, M.D., M.P.H.; Richard Haubrich, M.D.; A. Gregory DiRienzo, Ph.D.; Lynne Peeples, M.S.; William G. Powderly, M.D.; Karin L. Klingman, M.D.; Kevin W. Garren, Ph.D.; Tania George, Pharm.D.; James F. Rooney, M.D.; Barbara Brizz, M.H.S.Ed., B.S.N.; Umesh G. Lalloo, M.D.; Robert L. Murphy, M.D.; Susan Swindells, M.B., B.S.; Diane Havlir, M.D.; John W. Mellors, M.D.; the AIDS Clinical Trials Study Group Study A5142 Team
This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.